Shionogi grants J&J rights to beta secretase inhibitors for AD

Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize Shionogi's oral beta secretase inhibitors for Alzheimer's dis...